InMed Pharmaceuticals outlines key accomplishments from 2022 and provides business update and catalysts for 2023. Business update and upcoming milestones: INM-755 – Phase 2 clinical trial in the treatment of Epidermolysis Bullosa. To date, the Phase 2 clinical trial has enrolled 16 patients of its targeted 20 patients. Several additional prospective patients have been identified for screening at the clinical sites; therefore, the Company decided to extend the enrollment period to the end of March 2023. INM-088 – Advancing towards human trials: The Company continues to conduct the required preclinical work, including toxicology studies, and has planned several GLP studies in 2023 in advance of human clinical trials. On track to begin this clinical trial in 2024. INM-900 – Developing a new approach in neurodegenerative disease: InMed’s ipeline was expanded this year with the addition of our neurodegenerative disease program. With recent promising preclinical data, InMed plans to expedite its INM-900 program for the potential treatment of neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease. Novel cannabinoid analogs – protecting the R&D investment: InMed continues to develop a valuable library of novel, proprietary cannabinoid analogs. These analogs are being selectively screened and developed for targeting specific disease outcomes, safety profiles, and/or pharmacological properties such as improved delivery. In addition, these novel cannabinoid analogs are patentable, increasing their commercial attractiveness for internal development or as licensing candidates to other drug development companies.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on INM:
